What's Hot
View all perspectives
David Liew drdavidliew
2 years 5 months ago
Difficult to treat rheumatoid arthritis is expensive - to the health system, but also to society #EULAR2022 @RheumNow https://t.co/eM2Ih3kGL7
Aurelie Najm AurelieRheumo
2 years 5 months ago
🧨 Factors associated w/ Pulmonary Embolism in ORAL surveillance:
⚡️history of VTE ⚡️antidepressant use
⚡️BMI≥30
⚡️corticosteroid use
⚡️male gender
⚡️age ≥65
⚡️Hx of Hypertension
⚡️hormonal ttmt use
POS0239 #EULAR2022 @RheumNow https://t.co/pT6MDAUbjH
TheDaoIndex KDAO2011
2 years 5 months ago
Prof van Lear reviews #EULAR ’s 11 points to consider for difficult to treat RA (D2T RA) published here https://t.co/zOLiMChjx8 #EULAR2022 @rheumnow (1/n) https://t.co/mVjJ5A1VkW
Dr. Rachel Tate uptoTate
2 years 5 months ago
Dr. E. Loza reminds #EULAR2022 that it is important to measure response of patients when using clinical guidelines for treatment! It will help us adapt guidelines for the future to help patients. @RheumNow https://t.co/pMkpsMH44U
Dr. Antoni Chan synovialjoints
2 years 5 months ago
The reference is at https://t.co/Auwrimc0jt
Richard Conway RichardPAConway
2 years 5 months ago
Eun et al. South Korean population based study. n=138,592 RA patients. aHR dementia 1.19 (95%CI 1.16–1.23), Alzheimers 1.21 (95%CI 1.67-1.25), Vascular dementia 1.10 (95%CI 0.99-1.21) @RheumNow #EULAR2022 OP0271 https://t.co/URNYnYzuF6
Richard Conway RichardPAConway
2 years 5 months ago
Razmjou et al. Survival in RA-ILD patients with lung transplant comparable to other cohorts. Not surprisingly UIP pattern trended to worse outcome HR 7.13, p=0.06 @RheumNow #EULAR2022 OP0275 https://t.co/RJ1nMkHwRh https://t.co/iUENMhqiX3
Alberta Hoi alberta_hoi
2 years 5 months ago
Case reports of tofacitinib efficacy for calcinosis over last couple of years. Benefits were relatively quickly (within 3m) reported by Jiri Vencovsky #eular2022
Alberta Hoi alberta_hoi
2 years 5 months ago
Lisa Rider suggests that calcinosis is more commonly seen in JDM than adults maybe the result of the more prominent vasculopathy and IFN signature. #EULAR2022
David Liew drdavidliew
2 years 5 months ago
Always satisfying to see the big plenary hall in full flight #EULAR2022 @RheumNow https://t.co/DkzZCFvFw7
Dr. John Cush RheumNow
2 years 5 months ago
SLE trials update
Translating targeted therapy from bench to bedside has been more problematic in SLE than other autoimmune diseases.
https://t.co/xmYbgOplsm https://t.co/QUrtwAJqNl
Dr. Antoni Chan synovialjoints
2 years 5 months ago
Jacob van Laar on difficult to treat (D2T) RA. Comorbidities, fibromyalgia, obesity contribute to this. Associated with pauci-immune synovial pathotype. A consensus definition of D2T developed and est 5-20% of RA meet this criteria #EULAR2022 @RheumNow https://t.co/MgxJIJgxYw
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 Difficult to treat RA (D2TRA):
Synovial pathotype shows a pauci-immune phenotype, different from other forms of RA
@RheumNow https://t.co/0osG5Bb5yb
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 Difficult to treat RA
Which is the only independent risk factor in Netherlands study for D2TRA?
@RheumNow
Francois Nantel FNantel
2 years 5 months ago
Those #EULAR2022 vaccination bracelets are not the most discrete of things (and you can’t take them off). https://t.co/02NrLcqzT2
Poster Hall